Johnson & Johnson
At today's price, Johnson & Johnson (JNJ) is priced for today's economics sustained for ~8.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Johnson & Johnson is two large franchises under one roof, a drug business led by oncology and immunology and a medical-device business in cardiovascular, surgery, orthopaedics, and vision, and the recent growth is being carried by a handful of oncology drugs offsetting a steep decline in its old immunology anchor. • The defining risk is patent math: Immunology sales fell 11.8% to $15.7 billion in 2025 as STELARA lost exclusivity, and DARZALEX, now a $4 billion-a-quarter oncology engine, faces
Is JNJ overvalued? See what's priced in →
4,515 institutional managers reported holding JNJ in 13F filings for the quarter ended 2026-03-31. Together they hold about 70% of the company; the top 10 hold 34%. 216 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 26.7M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (3.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
JNJ has cut its share count 8.5% over the past five years, spending $25.52B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $5.14 a share annually. Cash returned over the past three years: $33.07B in dividends and $13.55B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at JNJ over the trailing three years: 2024: 1 buy totaling $147k; 2025: 1 buy totaling $258k. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
JNJ's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-01 | +0.5% | -8.0% |
| 2023-10-28 | -1.2% | +7.7% |
| 2024-02-17 | -2.2% | -5.5% |
| 2024-05-02 | +3.7% | -2.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
JNJ's latest 8-K filings: 2026-04-28 (items 5.07, 9.01); 2026-04-14 (items 2.02, 8.01, 9.01); 2026-01-21 (items 2.02, 9.01); 2025-10-14 (items 2.02, 8.01, 9.01); 2025-09-09 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.